Our CEO, Dr. Shlomi Madar, was invited to present at the NYU Langone Health Institute for Systems Genetics as part of its Nano Seminar Series. During the seminar, Dr. Madar presented SpotitEarly’s Bio-AI hybrid approach to breath-based cancer screening, explaining how trained canines and the LUCID platform work together to identify cancer signatures in breath samples. He also shared the journey from early research through our current U.S. clinical studies.

Dr. Madar was also invited to deliver a seminar at the Ernest Mario School of Pharmacy at Rutgers University, part of Rutgers Biomedical and Health Sciences. The invitation came from Tamara Minko, Distinguished Professor and Department Chair, a member of the Rutgers Cancer Institute of New Jersey and author of more than 400 peer-reviewed publications in journals including Nature Nanotechnology and Cancer Research.

Dr. Shlomi Madar participated in two HITLAB events in March. The first was an in-person networking evening in New York City, bringing together leaders across AI, healthcare, and digital health. The second was the HITLAB Breakthrough Alliance members-only webinar, where Dr. Madar presented SpotitEarly's Bio-AI Hybrid approach to breath-based cancer screening, covering the clinical data, the LUCID platform, and the company's path toward U.S. commercial availability.

Dr. Madar attended the Founders & Funders VC Reverse Pitch at the Jay Conference in New York City. The event flipped the traditional pitch format, with six venture capital firms, including RRE Ventures, Plum Alley, Forum Ventures, and Konvoy, taking the stage to present their investment theses directly to a room of founders. The evening provided direct insight into current funding priorities across the NYC venture landscape and an opportunity to connect with active investors in healthcare and technology.

SpotitEarly has launched its own podcast series, "The Long Game: Voices from the Healthfront" - a show dedicated to candid conversations at the intersection of health, science, and the future of diagnostics. Each episode features guests from across medicine, research, law, and technology, exploring the ideas and challenges shaping where healthcare is headed.

Our team joined Philadelphia's biotech community at the BioLabs space at The Curtis for an evening focused on scaling therapeutics through development. Events like these reflect our commitment to building within the broader biotech community as we approach our U.S. commercial launch.